Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)

Neuro-Oncology

Volumn 16, Issue , 2014, Pages vii36-vii47

  Wen, Patrick Y ^a   Cloughesy, Timothy F ^b   Ellingson, Benjamin M ^b   Reardon, David A ^a   Fine, Howard A ^c   Abrey, Lauren ^d   Ballman, Karla ^e   Bendszuz, Martin ^f   Buckner, Jan ^e   Chang, Susan M ^g   Prados, Michael D ^g   Pope, Whitney B ^b   Sorensen, Alma Gregory ^h   Van Den Bent, Martin ⁱ   Yung, Wai Kwan Alfred ^j  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e MAYO CLINIC ROCHESTER   (United States)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h SIEMENS CORPORATE RESEARCH   (United States)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Brain tumor; Endpoints; Neuroimaging; RANO; Workshop.

Indexed keywords

BIOASSAY; BRAIN NEOPLASMS; CANCER STAGING; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; GLIOMA; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; TRENDS;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; ENDPOINT DETERMINATION; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

EID: 84965187416     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou226     Document Type: Article

References (66)

1. Ostrom Q, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States 2006–2010. Neuro Oncol. 2013;15(Suppl 2):ii1–56.
2. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–477.
3. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425–437.
4. Weller M, Pfister SM, Wick W, et al. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol. 2013;14(9): e370–e379.
5. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492–507.
6. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842–1850.
7. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
8. Yung W, Prados M, Yaya T, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytomas of anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17(9):2762–2771.
9. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–4740.
10. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5): 740–745.
11. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3): 344–350.
12. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337–343.
13. Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Ann Rev Pathol. 2014; 9:1–25.
14. Alexander BM, Lee EQ, Reardon DA, et al. Current and future directions for phase II trials in high-grade glioma. Expert Rev Neurother. 2013;13(4):369–387.
15. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol. 2010;28(11): 1963–1972.
16. Section 505(d) of 1962 Amendment to the Federal Food, Drug, and Cosmetic Act. 1962.
17. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8(5):935–942.
18. Axelson M, Liu K, Jiang X, et al. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res. 2013;19(9):2289–2293.
19. FDA/AACR/ASCO Public Workshop on Brain Tumor Clinical Trial Endpoints. 2006.
20. Macdonald D, Cascino T, Schiold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277–1280.
21. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–722.
22. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008;10(2):162–170.
23. Provenzale JM, Ison C, Delong D. Bidimensional measurements in brain tumors: assessment of interobserver variability. Am J Roentgenol. 2009;193(6):W515–W522.
24. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization Offset Publication No 48 1979.
25. Miller A, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47(1):207–214.
26. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(2):205–216.
27. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
28. Warren KE, Patronas N, Aikin AA, et al. Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors. J Natl Cancer Inst. 2001;93(18):1401–1405.
29. Shah GD, Kesari S, Xu R, et al. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol. 2006;8(1):38–46.
30. Galanis E, Buckner JC, Maurer MJ, et al. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro Oncol. 2006;8(2):156–165.
31. Sorensen AG, Batchelor TT, Wen PY, et al. Response criteria for glioma. Nat Clin Pract Oncol. 2008;5(11):634–644.
32. Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. Am J Neuroradiol. 2008;29(3):419–424.
33. van den Bent MJ, Vogelbaum MA, Wen PY, et al. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald’s criteria. J Clin Oncol. 2009;27(18): 2905–2908.
34. Cairncross JG, Macdonald DR, Pexman JH, et al. Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology. 1988;38(5):724–726.
35. Watling CJ, Lee DH, Macdonald DR, et al. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol. 1994;12(9):1886–1889.
36. Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453–461.
37. Henegar MM, Moran CJ, Silbergeld DL. Early postoperative magnetic resonance imaging following nonneoplastic cortical resection. J Neurosurg. 1996;84(2):174–179.
38. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology. 2000;217(2):377–384.
39. Ulmer S, Braga TA, Barker FG 2nd, et al. Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology. 2006;67(9):1668–1670.
40. Finn MA, Blumenthal DT, Salzman KL, et al. Transient postictal MRI changes in patients with brain tumors may mimic disease progression. Surg Neurol. 2007;67(3):246–250; discussion 50.
41. Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/ progression measures for surgically delivered therapies for gliomas. Neurosurgery. 2012;70(1):234–243.
42. Nowosielski M, Wiestler B, Goebel G, et al. Progression types after anti-angiogenic therapy are related to outcome in recurrent glioblastoma. Neurology. 2014;82(19):1684–1692.
43. Huang RY, Rahman R, Pope WB, et al. Validation of RANO criteria: contribution of T2/FLAIR assessment in patients with recurrent glioblastoma treated with bevacizumab. J Clin Oncol. 2014;32: 5(suppl; abstr 2007).
44. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26):3212–3218.
45. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28(7): 1168–1174.
46. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83(5):588–593.
47. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007;9(1):29–38.
48. Gilbert MR, Wang M, Aldape K, et al. RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:15(suppl; abstr 2011).
49. Wen PY, Prados M, Schiff D, et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma. J Clin Oncol. 2010;28:15(suppl; abstr 2006).
50. de Groot JF, Lamborn KR, Chang SM, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011;29(19):2689–2695.
51. Iwamoto FM, Lamborn KR, Robins HI, et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 2010;12(8):855–861.
52. Fornage BD. Measuring masses on cross-sectional images. Radiology. 1993;187(1):289.
53. Vos MJ, Uitdehaag BM, Barkhof F, et al. Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology. 2003;60(5):826–830.
54. Rohde S, Massberg M, Reinhardt J, et al. [Impact of technical and morphological factors on the precision of software-based MR tumor volumetry: a phantom study]. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 2008;180(7): 654–661.
55. Boxerman JL, Zhang Z, Safriel Y, et al. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. Neuro Oncol. 2013;15(7): 945–954.
56. Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology. 2014;271(1): 200–210.
57. Radbruch A, Lutz K, Wiestler B, et al. Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro Oncol. 2012;14(2):222–229.
58. Gallego Perez-Larraya J, Lahutte M, Petrirena G, et al. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol. 2012;14(5): 667–673.
59. Ellingson BM, Malkin MG, Rand SD, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010;31(3):538–548.
60. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92(24):2029–2036.
61. Geer CP, Simonds J, Anvery A, et al. Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study. Am J Neuroradiol. 2012;33(3):556–562.
62. Barajas RF Jr., Chang JS, Segal MR, et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2009;253(2): 486–496.
63. Grosu AL, Astner ST, Riedel E, et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011;81(4):1049–1058.
64. Juhasz C, Dwivedi S, Kamson DO, et al. Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors. Mol Imaging. 2014;13:1–16.
65. Nagel AM, Bock M, Hartmann C, et al. The potential of relaxation-weighted sodium magnetic resonance imaging as demonstrated on brain tumors. Invest Radiol. 2011;46(9):539–547.
66. Jin T, Wang P, Zong X, et al. Magnetic resonance imaging of the amine-proton exchange (APEX) dependent contrast. Neuroimage. 2012;59(2):1218–1227.